MX2014010664A - Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso. - Google Patents

Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.

Info

Publication number
MX2014010664A
MX2014010664A MX2014010664A MX2014010664A MX2014010664A MX 2014010664 A MX2014010664 A MX 2014010664A MX 2014010664 A MX2014010664 A MX 2014010664A MX 2014010664 A MX2014010664 A MX 2014010664A MX 2014010664 A MX2014010664 A MX 2014010664A
Authority
MX
Mexico
Prior art keywords
methods
chop2
channelrhodopsin
mutations
identification
Prior art date
Application number
MX2014010664A
Other languages
English (en)
Other versions
MX360085B (es
Inventor
Zhuo-Hua Pan
Original Assignee
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wayne State filed Critical Univ Wayne State
Publication of MX2014010664A publication Critical patent/MX2014010664A/es
Publication of MX360085B publication Critical patent/MX360085B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/405—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención proporciona composiciones y kits que incluyen al menos un ácido nucleico o molécula de polipéptido que codifica una proteína ChR2 mutante. Los métodos de la invención incluyen administrar una composición que comprende un ChR2 mutante a un sujeto para conservar, mejorar, o restaurar la fototransducción. Preferiblemente, las composiciones y métodos de la invención se proporcionan a un sujeto que tiene visión disminuida, de este modo restaurar la visión a los niveles normales.
MX2014010664A 2012-03-05 2013-03-05 Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso. MX360085B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261606663P 2012-03-05 2012-03-05
PCT/US2013/029171 WO2013134295A1 (en) 2012-03-05 2013-03-05 Identification of channelrhodopsin-2 (chop2) mutations and methods of use

Publications (2)

Publication Number Publication Date
MX2014010664A true MX2014010664A (es) 2015-03-06
MX360085B MX360085B (es) 2018-10-10

Family

ID=47892055

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010664A MX360085B (es) 2012-03-05 2013-03-05 Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.

Country Status (17)

Country Link
US (2) US10947281B2 (es)
EP (1) EP2822964B1 (es)
JP (3) JP6395611B2 (es)
KR (1) KR102137717B1 (es)
CN (2) CN104334575A (es)
AU (4) AU2013230112A1 (es)
CA (1) CA2866405A1 (es)
DK (1) DK2822964T3 (es)
EA (1) EA201491643A1 (es)
ES (1) ES2703324T3 (es)
HK (1) HK1205744A1 (es)
HU (1) HUE040487T2 (es)
MX (1) MX360085B (es)
NZ (1) NZ629843A (es)
PL (1) PL2822964T3 (es)
PT (1) PT2822964T (es)
WO (1) WO2013134295A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007247929A1 (en) 2006-05-04 2007-11-15 Pennsylvania College Of Optometry Restoration of visual responses by In Vivo delivery of rhodopsin nucleic acids
US9453241B2 (en) 2010-05-04 2016-09-27 Wayne State University AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
HUE040487T2 (hu) 2012-03-05 2019-03-28 Univ Wayne State Csatornarodopszin-2 (CHOP2) mutációk azonosítása és alkalmazási eljárások
WO2014160281A2 (en) 2013-03-14 2014-10-02 Wayne State University Method of enhancing delivery of therapeutic compounds to the eye
CN105358527B (zh) 2013-07-08 2018-09-25 巴斯夫欧洲公司 肟酯光引发剂
CA2942324C (en) 2014-03-11 2024-05-14 Wayne State University A modified mglur6 promoter and methods of use
CA3022634A1 (en) 2016-05-03 2017-11-09 Wayne State University Method of enhancing viral-mediated gene delivery in the eye using proteosome inhibitors
US20190218256A1 (en) * 2016-06-03 2019-07-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Mutant light-inducible ion channel of channelrhodopsin
CN110023327B (zh) * 2016-08-29 2024-02-27 韦恩州立大学 在具有改善光敏感性的通道视蛋白变体中突变的识别及其使用方法
JP6779546B2 (ja) * 2016-11-06 2020-11-04 ナノスコープ テクノロジーズ エルエルシーＮａｎｏｓｃｏｐｅ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｌｃ 視力回復のための多特性オプシンによる光遺伝学的調節及びその別の用途
WO2018189247A1 (en) * 2017-04-12 2018-10-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. New optogenetic tool
CN111542316A (zh) * 2017-12-04 2020-08-14 实验室救助者公司 用于治疗眼睛后段疾病的包含羟苯磺酸的眼科局部组合物
JP6567153B1 (ja) * 2018-09-28 2019-08-28 学校法人東北工業大学 対象化合物の特性の予測を行うための方法、コンピュータシステム、プログラム

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4498919A (en) 1983-10-31 1985-02-12 Corning Glass Works Method for making colored photochromic prescription ophthalmic lenses
US6610287B1 (en) 1990-04-16 2003-08-26 The General Hospital Corporation Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
WO1998048027A2 (en) 1997-04-21 1998-10-29 University Of Florida Materials and methods for treatment of retinal diseases
CA2346262A1 (en) 1998-09-17 2000-03-23 University Of Florida Methods for treatment of degenerative retinal diseases
AU2001255575B2 (en) 2000-04-28 2006-08-31 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with aav5 capsids and aav5 vectors pseudotyped in heterologous capsids
WO2002082904A2 (en) 2001-04-13 2002-10-24 The Trustees Of The University Of Pennsylvania Method of treating or retarding the development of blindness
WO2003016486A2 (en) 2001-08-16 2003-02-27 Sloan Kettering Institute For Cancer Research Bio-synthetic photostimulators and methods of use
DE10216005A1 (de) 2002-04-11 2003-10-30 Max Planck Gesellschaft Verwendung von biologischen Photorezeptoren als direkt lichtgesteuerte Ionenkanäle
AU2003249318A1 (en) 2002-07-18 2004-02-09 The General Hospital Corp. Method for augmenting vision in persons suffering from photoreceptor cell degeneration
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7427138B2 (en) 2003-11-05 2008-09-23 Neurovision, Inc. Method and apparatus for improving visual perception
WO2007024391A2 (en) 2005-07-22 2007-03-01 The Board Of Trustees Of The Leland Stanford Junior University Light-activated cation channel and uses thereof
AU2007247929A1 (en) 2006-05-04 2007-11-15 Pennsylvania College Of Optometry Restoration of visual responses by In Vivo delivery of rhodopsin nucleic acids
US9453241B2 (en) 2010-05-04 2016-09-27 Wayne State University AAV-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
US8748578B2 (en) 2010-09-08 2014-06-10 Max-Planck-Gesellschaft zur Foerderrung der Wissenschaften e.V. Mutant channelrhodopsin 2
HUE040487T2 (hu) * 2012-03-05 2019-03-28 Univ Wayne State Csatornarodopszin-2 (CHOP2) mutációk azonosítása és alkalmazási eljárások
KR101639859B1 (ko) * 2014-03-06 2016-07-14 포항공과대학교 산학협력단 광 자극에 의한 미토콘드리아 활성의 시공간적 가역 조절 방법

Also Published As

Publication number Publication date
JP2018134098A (ja) 2018-08-30
US20220033449A1 (en) 2022-02-03
CN104334575A (zh) 2015-02-04
CA2866405A1 (en) 2013-09-12
NZ629843A (en) 2017-03-31
US20150044181A1 (en) 2015-02-12
EP2822964A1 (en) 2015-01-14
KR20140132401A (ko) 2014-11-17
PT2822964T (pt) 2018-11-29
AU2019216638B2 (en) 2021-07-08
HK1205744A1 (en) 2015-12-24
JP6395611B2 (ja) 2018-09-26
AU2017239601A1 (en) 2017-10-26
AU2021245195A1 (en) 2021-11-04
JP2019193656A (ja) 2019-11-07
EP2822964B1 (en) 2018-08-22
AU2019216638A1 (en) 2019-09-05
US10947281B2 (en) 2021-03-16
WO2013134295A1 (en) 2013-09-12
AU2013230112A1 (en) 2014-09-25
AU2017239601B2 (en) 2019-05-16
NZ727041A (en) 2022-01-28
JP2015510759A (ja) 2015-04-13
PL2822964T3 (pl) 2019-05-31
ES2703324T3 (es) 2019-03-08
EA201491643A1 (ru) 2015-02-27
AU2021245195B2 (en) 2023-09-28
MX360085B (es) 2018-10-10
KR102137717B1 (ko) 2020-07-27
HUE040487T2 (hu) 2019-03-28
DK2822964T3 (en) 2018-12-10
CN111378020A (zh) 2020-07-07

Similar Documents

Publication Publication Date Title
MX360085B (es) Identificacion de mutaciones de channelopsin-2 (chop2) y los metodos de uso.
WO2017191274A3 (en) Rna encoding a therapeutic protein
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
BR112018008766A2 (pt) variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos
PE20170771A1 (es) Composiciones y metodos de uso para tratar trastornos metabolicos
CY1120772T1 (el) ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ
MX2017014532A (es) Vacunas para el tratamiento y prevencion del cancer.
EA201892619A1 (ru) Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
MX2021010668A (es) Proteinas de fusion de citoquinas.
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
MX2009002816A (es) Proteinas de fusion de albumina.
MX2012001346A (es) Polipeptidos del factor ix modificados y usos de los mismos.
PH12014501991B1 (en) Phenicol antibacterials
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
TR201910117T4 (tr) OspA nın mutant fragmanları ve bunlara ilişkin yöntemler ve kullanımları.
EA201491513A1 (ru) Рекомбинантные штаммы escherichia coli
PH12015500771A1 (en) Novel fc gamma receptor iib variants
BR112013005711A2 (pt) método para tratar um tumor, mutante, molécula de ácido nucleico isolada, construção de expressão, composição, e, método para administrar uma terapia
MX2019002321A (es) Identificación de mutaciones en variantes de opsina de canal con sensibilidad a la luz mejorada y métodos de uso de estas.
GB201019467D0 (en) Therapeutic agent
BR112018016920A2 (pt) indutor da imunidade, célula apresentadora de antígeno isolada, célula t isolada, polipeptídeo, agente para tratar ou prevenir o câncer e método de tratamento ou prevenção do câncer
GB201204283D0 (en) Polypeptides and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration